Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBL-B inhibitor
- Development stage
- Preclinical
- Lead developer
- Aurigene Oncology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CBL-B inhibitor is an oral small molecule therapeutic candidate being developed by Dr. Reddy's Laboratories and its oncology-focused subsidiary, Aurigene Oncology, for the treatment of multiple solid tumors. The drug targets Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ubiquitin ligase that serves as a critical intracellular immune checkpoint. CBL-B negatively regulates the activation of T cells and natural killer (NK) cells; its inhibition is intended to lower the threshold for immune cell activation and prevent the induction of T-cell anergy within the tumor microenvironment. By 'removing the brakes' on the immune system, this small molecule aims to enhance anti-tumor immunity and potentially overcome resistance to traditional cell-surface checkpoint inhibitors. The program is currently in the preclinical stage of development.
- Other names
- Dr. Reddy's Labs-CBL-B-small molecule-multiple solid tumorsCBL-B inhibitorDr. Reddy's CBL-B inhibitor
02
Targets
CBLB (CBL-B)
Beyond the preview
Go deeper on CBL-B inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBL-B inhibitor.